In spring 2024, the ACR is expected to release guidelines to help inform the screening, monitoring, and treatment of interstitial lung disease (ILD) in people with SARDs.
Efficacy, safety findings for the use of TNF inhibitors vs other biologic disease-modifying antirheumatic drugs in treating RA-ILD contrast with those of some smaller observational studies.
"Guidance was needed for which tests to use for screening and monitoring this particular disease," said lead author Sindhu R. Johnson, MD, PhD. The full manuscript will be published by early 2024.